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Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary
infection caused by a previously unidentified coronavirus (CoV), likely
transmitted to humans by infected camels. There is no licensed vaccine
or antiviral for MERS, therefore new prophylactic and therapeutic strat-
egies to combat human infections are needed. In this study, we de-
scribe, for the first time, to our knowledge, the isolation of a potent
MERS-CoV–neutralizing antibody from memory B cells of an infected
individual. The antibody, named LCA60, binds to a novel site on the
spike protein and potently neutralizes infection of multiple MERS-CoV
isolates by interfering with the binding to the cellular receptor CD26.
Importantly, using mice transduced with adenovirus expressing human
CD26 and infectedwithMERS-CoV,we show that LCA60 can effectively
protect in both prophylactic and postexposure settings. This antibody
can be used for prophylaxis, for postexposure prophylaxis of individu-
als at risk, or for the treatment of human cases of MERS-CoV infec-
tion. The fact that it took only 4 mo from the initial screening of B cells
derived from a convalescent patient for the development of a stable
chinese hamster ovary (CHO) cell line producing neutralizing antibodies
atmore than 5 g/L provides an example of a rapid pathway toward the
generation of effective antiviral therapies against emerging viruses.
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Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emergent subgroup C betacoronavirus that was
detected for the first times in June and September of 2012, when
two cases of severe infections were identified in the Eastern
Mediterranean region (1, 2). As of June 29, 2015, 1,379 human
infections with 531 deaths have been confirmed in 26 countries
in the Middle East, Europe, North Africa, Asia, and Americas,
including the recent outbreak in South Korea caused by an in-
dividual who traveled to the Middle East, which caused 164
infections and 23 deaths (www.ecdc.europa.eu). MERS-CoV
causes severe infection of the lower respiratory tract, similar to
the Severe Acute Respiratory Syndrome CoV (SARS-CoV) that
appeared in China in 2002. Several cases of human-to-human
transmission have been reported in health care workers and
family clusters, but at the current time there is no evidence of
sustained human-to-human transmission.
SARS-CoV and MERS-CoV belong to the B and C betacor-
onavirus lineages and have been shown to bind to cellular re-
ceptors ACE2 and CD26 [also known as dipeptidyl peptidase
4 (DPP4)], respectively. Of note, SARS-CoV targets ciliated
bronchial epithelial cells and type I and type II pneumocytes,
whereas MERS-CoV infects type II pneumocytes and non-
ciliated bronchial cells. These differences might account for the
different rates of human-to-human transmission, which was high
for SARS-CoV and is moderate to low for MERS-CoV. The two
viruses differ also in the duration of their epidemic, which was
limited for SARS-CoV (from November 2002 to July 2003) and
long-lasting for MERS-CoV, which appeared in 2012 and con-
tinues to circulate in the Middle East.
As to the zoonotic reservoir, both MERS-CoV and SARS-
CoV probably originated in bats (3, 4) with dromedary camels
serving as intermediate hosts for the human MERS-CoV in-
fection and palm civets and raccoon dogs for SARS-CoV (5).
Dromedary camels have a close association with humans in the
affected areas. Of note, whereas in humans MERS-CoV infects
the lower respiratory tract, rendering human-to-human transmission
inefficient, in camels the virus infects the upper respiratory tract and
is present in nasal secretions at high concentrations, which favors
transmission to humans and other camels. However, the mechanisms
of transmission from camels to humans and from humans to humans
as well as the global incidence in humans are still unclear. Camels
show no or mild symptoms, and antibodies found in banked sera
samples show that the virus has been present in the animals for at
least the past 20 y (6). In addition, most of the patients described
appeared to have been infected in hospitals, from other MERS
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patients, and even many of those who became infected outside a
hospital report no exposure to camels. Recent epidemiological
data suggest that more than ∼45,000 people in Saudi Arabia
were seropositive for a MERS infection, implying that the
majority of infections may not detected, the case fatality rate is
lower than current estimates of about 40%, or significant levels
of unreported severe disease have been misdiagnosed over the
past 5–20 y.
The trimeric S protein of MERS-CoVmediates receptor binding
and membrane fusion and is the major target for neutralizing an-
tibodies (7, 8). The structure of the cellular receptor (CD26), which
is conserved across many species (9), and the complex of CD26
with the receptor binding domain (RBD) of the S protein have
been determined by X-ray crystallography (10, 11).
Recently, two groups have used nonimmune human antibody-
phage display libraries to isolate neutralizing antibodies to MERS-
CoV (12, 13). The antibody 3B11 described by Tang et al. (12)
showed neutralizing activity against some but not all strains. m336,
a second antibody described more recently by Ying et al. (13),
showed high neutralizing potency and used the same VH gene (i.e.,
VH1-69) with high homology to 3B11 in the HCDR3, suggesting
that the two antibodies might have a similar mode of interaction.
This hypothesis is supported by the analysis of m336 escape mu-
tants. Here we describe for the first time, to our knowledge, the
isolation of a potent neutralizing human monoclonal antibody from
the memory B cells of an infected patient that might be developed
for the prevention and treatment of MERS-CoV infections.
Results
Rapid Isolation and Scaled-Up Production of a Potent MERS-CoV
Human Neutralizing Antibody. A 49-y-old man from Qatar (14)
was hospitalized with severe respiratory failure, requiring extra-
corporeal membrane oxygenation for over 200 d at St. Thomas’s
Hospital in London. Diagnosis was established by RT-PCR de-
tection of corona virus, which was found to be a novel virus (14),
subsequently isolated, and thereafter defined as London1/2012
strain. Serum samples and mononuclear cells were obtained at
two time points. A pseudotyped luciferase-based MERS-CoV
neutralization assay was developed using the sequence of the S
protein of the autologous virus (i.e., London1/2012). The donor
serum samples obtained 5 and 8 mo after infection showed only
modest neutralizing activity (Fig. 1A), a finding that illustrates
the difficulty of obtaining neutralizing antibodies for passive
serotherapy from infected patients. IgG memory B cells were
immortalized under clonal conditions, and supernatants were
screened using a pseudotyped neutralization assay and an ELISA
on fixed MERS-CoV–infected cells (Fig. 1B).
A single B-cell culture out of ∼4,600 showed neutralizing ac-
tivity, indicating a very low frequency of MERS-CoV–specific B
cells, which is consistent with the low serum neutralizing titer.
The antibody isolated from this culture, dubbed LCA60, showed
an IC50 value of 10 ng/mL against the London1/2012 MERS-
CoV pseudovirus (Fig. 1C). We also isolated a nonneutralizing
antibody (dubbed LCA57) from the ELISA screening. Both
LCA60 and LCA57 bound to the S protein from the EMC strain,
as determined by ELISA (Fig. 1D), but not to the S protein of
HKU4.2 (group IIC, 67% amino acid identity) and HKU3 (group
IIB, 30% amino acid identity). LCA60 was confirmed to neu-
tralize, with high and comparable efficiency, infectious MERS-
CoV from the London patient as well as additional isolates
obtained from Saudi Arabia and Jordan (IC50 values, 279 ng/mL
for London1/2012, 150 ng/mL for EMC/2012, and 110 ng/mL for
the Jordan-N3/2012 isolate) (Fig. 1E). These results indicate that
LCA60 is 10-fold more potent than 3B11 and comparable to
m336. The binding rate constants were determined by surface-
plasmon resonance (Fig. 2). LCA60 showed subnanomolar affinity
for the S protein [equilibrium dissociation constant (KD) equiv-
alent to 0.12 nM], which was ∼300-fold higher compared with
3B11. In addition, the affinity of LCA60 binding to the RBD was
∼500-fold higher compared with CD26.
LCA60 uses VH3–15*01 and VL2–23*01, has a 18-amino-acid
HCDR3, and carries 17 amino acid substitutions in VH and 12 in
VL. In silico analysis of the antibody sequence did not reveal any
sequence motif that may impact expression or stability. A codon-
optimized gene was synthesized and cloned into a double gene
expression vector that was used to transfect the Lonza CHO-K1SV-
GS-KO cell line. After a round of selection followed by subcloning,
a high-producing research cell line, called LCA60.273.1, was iso-
lated. This line showed high stability of expression and produced
4–5 g/L under fed-batch conditions in shake flasks. The whole
process of isolating the antibody and producing the stable cell line
was completed in less than 4 mo. This illustrates the feasibility of
rapidly developing a human monoclonal neutralizing antibody in
response to newly emerging life-threatening infections.
Isolation of Viral Escape Mutants and Molecular Modeling of the
RBD–LCA60 Complex. LCA60 was tested against a panel of
monoclonal antibody-resistant mutants (MARMs) that were
previously selected using the phage-derived antibodies 1E9
(P547S), 1F8 (R542G), 3C12 (Y540H), and 3B12 (L506F/
T512A), which were mapped to three different regions in the
RBD (12). Of note, all these MARMs were efficiently neutralized
by LCA60 (Fig. 1F). These results indicate that LCA60 binds to a
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Fig. 1. Isolation of the LCA60 antibody from the memory B cells of a MERS-
CoV–infected individual. MERS survivor plasma samples (two time points, T1
and T2, corresponding to 5 and 8 mo after infection, respectively) (A) and
supernatants from EBV-immortalized B-cell cultures (B) were tested for the
presence of MERS-CoV pseudovirus (London1/2012, abbreviated as LD1)
neutralizing antibodies. LCA60 and LCA57 antibodies were tested for their
ability to neutralize the homologous London1/2012-CoV (C) and bind to S
protein (EMC/2012) (D). The LCA60 antibody was further tested against three
infectious MERS-CoV isolates (E) and several EMC MERS-CoV MARMs (F).
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distinct site on the S protein. To better define the LCA60 epitope,
we performed viral escape studies. Upon three rounds of selection
with LCA60, two independent MARMs were isolated (Fig. 1F).
The sequence of the S genes showed that both MARMs carried two
identical mutations, V33A in the N-terminal region and E536A in
the RBD (Fig. S1).
To map the LCA60 epitope, we used a combination of compu-
tational predictions and experimental validation. Computational
docking predicts the atomic-level 3D structure of a multimolecular
complex starting from the separated structures of the individual
components, in this case RBD and LCA60. The experimental
structure of MERS-CoV RBD was available (10, 11), whereas the
structure of LCA60 was predicted by homology modeling according
to the canonical structure method (15). The CDR loops of an an-
tibody can adopt a limited and predictable set of conformations,
dependent on length and presence of specific amino acids at key
positions, with the exception of the HCDR3 loop, which can adopt
variable and often flexible conformations due to the high variability
in sequence and length (Fig. S2).
To cover a larger conformational space and to limit the impact
of possible modeling inaccuracies, we generated multiple models
of LCA60 and docked each of them independently to the
MERS-CoV RBD structure using the RosettaDock program
(16). The docking algorithm identified two equally plausible
models of the LCA60–RBD complex (Fig. 3 A and B and Fig.
S3), which we were able to discriminate according to their
agreement with experimental data. In both models, the antibody
interacts with RBD residues around K493, but only in model A
does the antibody interact with residues in the 540–543 region.
Introducing mutations in the latter region is expected to affect
antibody binding if model A is correct, whereas these mutations
should not affect binding if model B is correct. We thus pro-
duced 14 mutants of the S protein spanning different regions of
the RBD, including the MARM mutations described above.
LCA60 and LCA57 were then tested for their ability to bind to
cells expressing full-length S mutants. Whereas LCA57 bound to
all mutants, LCA60 did not bind T489A, K493A, and E565A and
bound poorly to LCA60–MARM E536A (Table S1). These re-
sults allowed us to discard model A and select model B as the
most consistent with experimental data. Importantly, the four
positions that affected LCA60 binding (T489, K493, E565, and
E536) are conserved in all natural isolates described to date,
including the most recent isolates from the outbreak in South
Korea (Fig. S4).
According to model B, the LCA60 footprint on the RBD
partially overlaps with that of the CD26 receptor (Fig. 3 C and
D), suggesting that LCA60 neutralizing activity results from in-
terference with the RBD–CD26 interaction. Results of sur-
face plasmon resonance (SPR) cross-competition experiments
showed that LCA60 and 3B11 compete for binding to RBD,
whereas LCA57 did not compete with either LCA60 or 3B11. In
addition, LCA60 and 3B11, but not LCA57, prevented the
binding of CD26 to RBD (Fig. 4). This is in agreement with the
structural model presented and indicates that LCA60 and 3B11
neutralize MERS-CoV by blocking binding to its cellular receptor.
LCA60 Prophylactic and Postexposure Efficacy in MERS-CoV–Susceptible
Mice. The LCA60 produced in the CHO cell line was tested in
BALB/c mice that were sensitized to MERS-CoV infection by
transduction with adenoviral vectors expressing human CD26
(17). In this model, as a result of virus receptor expression on lung
Fig. 2. LCA60 binds to S protein with high affinity. SPR sensograms showing
the CoV S protein (EMC/2012) association and dissociation with the LCA57,
LCA60, 3B11, and CD26 receptor. The antibodies and the receptor were
immobilized on the sensor surface, followed by injection of S protein at the
concentrations indicated in the figure. The line fitted to the experimental
data and used to calculate the binding affinities is drawn in gray. KD values
are reported in the table.
Fig. 3. Computational models of MERS-CoV RBD in complex with antibody
LCA60. (A and B) Structures of the complex between mAb LCA60 (light green
and orange cartoons) and RBD–MERS (white surface) obtained by compu-
tational docking. S protein mutants that affect (red) or do not affect (blue)
antibody binding are shown. Only model B is consistent with the muta-
genesis data. (C) Experimental structure of the complex between CD26 (light
blue cartoon) and MERS–RBD [Protein Data Bank (PDB) ID code 4KR0].
(D) Footprint of LCA60 antibody (light green) and CD26 (light blue) on the
surface of MERS–RBD (white). Residues in contact with both LCA60 and CD26
are shown in violet.
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cells, MERS-CoV gains entry to lungs and replicates as in human
disease. However, replication and pathology are limited and the
virus is cleared by day 7. hCD26-transduced mice were treated by
i.p. injection of LCA60 at 1, 5, or 15 mg/kg either 1 d before (day
–1) or 1 dafter intranasal infection (day +1) with EMC and London
strains. The results showed that, in both prophylactic and post-
exposure settings, LCA60 treatment led to a 2–4 log reduction in lung
viral titers on day 3 with undetectable levels obtained in nearly all
mice by day 5 (Fig. 5 A–D). In the same model, LCA60 administered
on day +1 by intranasal delivery resulted, when titers were measured
at day 3, in a significant dose-dependent inhibition of viral titers that
was still detectable when the antibody was dosed at 0.12 mg/kg
(Fig. 5E).
We also used the mouse infection model to test whether the
LCA60 MARM virus (carrying E536A and V33A mutations)
might have an impaired fitness in vivo. The results showed that,
as expected, LCA60 antibody was not effective prophylactically
and that the mutant virus could replicate in CD26-transduced
mice to levels comparable to the EMC parental virus (Fig. S5).
We noted, however, that plaques of the LCA60 MARM were
smaller in size compared with those of the original EMC strain.
The efficacy of LCA60 was also evaluated in a more stringent
model of MERS-CoV–infected IFN-α/β receptor-deficient mice
(IFNAR-KO). Once transduced with human CD26, these mice
developed a more profound clinical disease following MERS-
CoV infection, as shown by a body weight loss, prolonged virus
shedding, and gross changes in histology (17). Administration of
LCA60 at 15 mg/kg i.p. 1 d after infection reduced lung viral
titers by more than three logs in mice infected with both London
and EMC strains on both day 3 and 5 (Fig. 6 A and B). In ad-
dition, LCA60 prevented body weight loss as well as perivascular
and peribronchial lymphoid infiltration that in control mice
further progressed to an interstitial pneumonia (Fig. 6 C and D).
In the same model, LCA60 administered at 10 mg/kg on day +1
by intranasal delivery resulted in a significant inhibition of viral
titers on day 2, and to a major extent on day 4, compared with
control mice (Fig. 6F).
Discussion
Clinical studies in patients with severe viral pneumonia caused by
viral infections have shown that convalescent sera can have a
therapeutic benefit. This has been demonstrated for infections
including Spanish influenza pneumonia during 1918–1919 (18),
SARS-CoV (19), H5N1 influenza A virus (20), and more re-
cently severe H1N1 influenza A virus infection (21). However,
the lack of availability of convalescent sera and the low antibody
titers, like in the case of the patient described in this study,
significantly limit the utility of this approach. Rapid isolation,
purification, and production of specific human neutralizing mono-
clonal antibodies represent a safe, controlled, affordable, and un-
limited source of the most potent antibodies present in convalescent
sera, overcoming the limitations of patient-derived convalescent sera.
Due to the continuous emergence of new zoonotic viruses,
there is a need to develop rapid pathways for the identification
and development of new treatments for prophylaxis, postexposure
prophylaxis, and therapy. This study illustrates an example of this
approach for MERS. In particular, we have shown that a human
neutralizing antibody can be isolated, characterized, and produced
in large amounts in cell lines compatible for human use in a short
period of only a few months. The efficiency of the B-cell in-
terrogation method used was instrumental in isolating a rare cell
from a small blood sample obtained from an individual who had
mounted only a modest neutralizing antibody response. The iso-
lation of antibodies using phage libraries can also be rapid but
bears some risks for their development. In particular, due to
scrambled VH–VL pairing, phage-derived antibodies carry a risk of
autoreactivity and may not express well in mammalian cells, a fact
that has significantly hampered their clinical development. Our
data also show a rapid path for epitope mapping and mechanism of
action studies using experimentally validated computational
docking, viral escape mutant, and cross-competition assays.
Fig. 4. LCA60 blocks MERS-CoV RBD binding to its cognate cellular receptor CD26. Cross-competition SPR assay was used to investigate the epitopes region;
LCA57, LCA60, 3B11 antibodies and CD26 receptor (ligands) were first immobilized on different channels (vertical column) of the SPR chip. The spike protein
was subsequently injected to form the complexes; finally, the three antibodies and the receptor (analytes) were injected one in each horizontal row. If a
binding event is detected (red borders rectangle), the analyte has a different epitope from the ligand immobilized in the first step; if no binding is detected,
ligand and analyte share overlapping epitopes.
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This study also takes advantage of recent developments of
animal models for emerging respiratory viral infections based on
transient expression of human receptors in wild-type or immune-
deficient mice. In this model, our antibody showed high efficacy
both in prophylaxis and therapy, with reduction of lung viral titers
of 100–1,000-fold, as well as reduction of signs and pathology.
There is increasing evidence that antibodies can be efficiently
delivered through nebulization (22–24). It was interesting to find
that when administered intranasally LCA60 was effective in both
mouse models and even when tested at concentrations as low as
0.12 mg/kg. These results suggest that it would be important to
evaluate the local delivery of an antibody by nebulization, a route
of administration that offers considerable advantages over the
parenteral route, such as lower dosage, higher antibody concen-
tration in lung fluids, and ease of multiple administrations.
LCA60 binds to an epitope in the S protein RBD with sub-
nanomolar affinity and potently neutralizes MERS-CoV infection
of multiple isolates. The epitope has partial overlap with the RBD–
CD26 receptor interface, and antibody binding prevents interaction
of the viral RBD with its cellular receptor. Therefore, inhibition
of virus–receptor interactions is at least one major mechanism of
LCA60 neutralization. Experimentally validated computational
docking as well as generation of escape variants allowed identi-
fication of RBD residues critical for binding and neutralization.
LCA60 has a novel epitope that is not affected by escape mu-
tants generated by 3B11 and other phage-derived neutralizing
antibodies.
The use of a single neutralizing antibody bears the risk of
selecting escape mutants in vivo, a fact that has been demon-
strated in vitro for LCA60 and the other described antibodies.
The use of two antibodies against nonoverlapping sites may offer
a solution to this problem. However, to date, all of the MERS-
CoV neutralizing antibodies cross-compete, a finding that might
not provide a rationale for combining these antibodies. Although
recognizing that the full spectrum of MERS-CoV antigenic
variation is still under study, it should be noted that the residues
that are important for LCA60 binding are conserved in all
MERS-CoV isolates, whereas 3B11 fails to recognize the London
isolate due to the L506F mutation.
This work demonstrates the feasibility of using monoclonal
antibodies isolated from memory B cells of survivors as a rapid
response platform to protect the public health from emerging
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Fig. 5. Passive transfer of LCA60 confers protection to mice prophylactically
and therapeutically. We transferred 200 μL of diluted antibodies in PBS into Ad5-
hDPP4–transduced BALB/c mice (6 wk, female) intraperitoneally 1 d before (A
and C) or after (B and D) MERS-CoV EMC/2012 (EMC) (A and B) or London1/2012
(LD1) (C and D) infection. Mice were then infected with 1 × 105 pfu MERS-CoV
intranasally. Virus titers in the lungs were measured at the indicated time points.
(E) Intranasally delivered LCA60 protected MERS-CoV–infected mice. We trans-
ferred 50 μL of diluted antibodies in PBS intranasally into Ad5-hDPP4–transduced
BALB/c mice (6 wk, female) 1 d after infection with 1 × 105 pfu of the EMC/2012
strain of MERS-CoV. Virus titers in the lungs were measured on day 3 after in-
fection. Titers are expressed as pfu/g tissue. n = 3–4 mice per group per time
point. *P < 0.05 compared with hIgG1 group.
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Fig. 6. LCA60 protected MERS-CoV–infected IFNAR-KO mice. We trans-
ferred 200 μL of diluted antibodies (15 mg/kg) in PBS into Ad5-hDPP4–
transduced IFNAR-KO mice (6–12 wk) intraperitoneally 1 d after MERS-CoV
infection. Mice were then infected with 1 × 105 pfu MERS-CoV London1/2012
strain (A) or EMC/2012 strain (B–E) intranasally. Virus titers in the lungs were
measured at the indicated time points. Additional groups of animals were
monitored daily for morbidity, mortality, and body weight loss up to 14 d
after infection (C). The histologic analysis was performed on animals killed
on day 7 after infection (D and E). Mice were anesthetized and transcardially
perfused with PBS followed by zinc formalin. Lungs were removed, fixed in
zinc formalin, and paraffin embedded. Sections were stained with hema-
toxylin and eosin for histological analysis. (F) Intranasally delivered LCA60-
protected MERS-CoV–infected mice. We transferred 50 μL of diluted anti-
body (10 mg/kg) in PBS intranasally into Ad5-hDPP4–transduced IFNAR-KO
mice (6 wk, female) 1 d after infection with 1 × 105 pfu of the EMC/2012
strain of MERS-CoV. Virus titers in the lungs were measured at the indicated
time points. Titers are expressed as pfu/g tissue. n = 3 mice per group per
time point. *P < 0.05 compared with hIgG1 or PBS groups.
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viruses like SARS or MERS-CoVs, or others, which are likely to
continue to emerge.
Methods
Detailed information about generation of anti–MERS-CoV monoclonal anti-
bodies, screening, in vitro characterization of antibodies, and testing in vivo can
be found in SI Methods. All protocols in animal experiments were approved by
the University of Iowa Institutional Animal Care and Use Committee.
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